USPTO serial 79291480
NANOPRIMER
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 20, 2021
- Examiner
- SAITO, KIM
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with NANOPRIMER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $797*
Plus Government fees of $975
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michele S. Katz
Michele S. Katz Advitam IP, LLC150 S. Wacker DriveSuite 2400Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Products for medical use especially for metabolic pathways to prevent and treat acid-base imbalance, metabolic brain diseases, disorders of calcium metabolism, DNA repair-deficiency disorders, glucose metabolism disorders, hyperlactatemia, iron metabolism disorders, lipid metabolism disorders, malabsorption syndromes, metabolic syndrome X, inborn error of metabolism, mitochondrial diseases, phosphorus metabolism disorders, porphyrias, proteostasis deficiencies, metabolic skin diseases, wasting syndrome and water-electrolyte imbalance; products for medical use especially for the diagnosis and treatment of tumors; preparations for medical use especially for modifying the bioavailability of therapeutic agents; preparations for medical use especially for modifying liver functions to prevent and treat alcohol-related liver disease, non-alcoholic fatty liver disease, hepatitis, haemochromatosis, primary biliary cirrhosis and liver cancer; preparations for medical use for modifying the functions of the reticuloendothelial system to decrease reticuloendothelial system ability to trap and metabolize therapeutic agents such as nanomedicines, monoclonal antibodies, antibody-drug conjugates, small molecules, and to prevent and treat Gaucher's disease, mastocytosis, and histiocytosis; preparations based on nanomaterials for the delivery of therapeutic agents combined with nucleic acid, small molecules, proteins and peptides; nanoparticles for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, organ transplant rejection; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, organ transplant rejection; enzymes for medical use; enzyme preparations for medical use; diagnostic products for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; drugs for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; medicines for human to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; tonics for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; antibiotics; antiseptics; chemico-pharmaceutical preparations for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; pharmaceutical preparations for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; dietetic substances preparations adapted for medical use; remedies for human medicine for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection | ACTIVE | — |
| 042 | Scientific and technological services as well as, namely, research and design services particularly in the field of nanomedicine which is nanotechnology applied to medicine; biological research; research in bacteriology; conducting early evaluations in the field of new pharmaceuticals; design and development of new products for third parties; conducting clinical trials for others in the field of new pharmaceuticals; research services in the field of new pharmaceuticals; chemical analysis; chemical research; chemical engineering; chemical research and analysis services in the field of physico-chemical characterization and concept design; engineering work, namely, surveying; research and development of new products for third parties; technical research in the field of new pharmaceuticals; radiobiology research; research in nanoscience and nanotechnology, especially applied to medicine | ACTIVE | — |
| 044 | Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Curadigm
- Other trademarks owned by NANOBIOTIX
- Other trademarks owned by Curadigm
- Other trademarks owned by Curadigm
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NANOPRIMER
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 20, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Dec 27, 2024 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Dec 13, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 4, 2021 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Nov 17, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 17, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 20, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 20, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 4, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 4, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 2, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 14, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 14, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 14, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 26, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 26, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 26, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 26, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 26, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 26, 2021 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Mar 26, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 19, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 18, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 18, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 29, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 6, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 5, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 18, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 17, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 27, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 18, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 14, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 13, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |